

Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

COV504

RRID:CVCL_2424

Type: Cell Line

Proper Citation

RRID:CVCL_2424

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2424

Proper Citation: RRID:CVCL_2424

Description: Cell line COV504 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Ovarian carcinoma

Defining Citation: [PMID:8436435](#), [PMID:22460905](#), [PMID:23839242](#), [PMID:25230021](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:28273451](#), [PMID:30894373](#), [PMID:31068700](#)

Comments: Population: Caucasian., Part of: OCCP ovarian cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: COV504

Synonyms: Cov504, COV 504

Cross References: EFO:EFO_0006385, ArrayExpress:E-MTAB-2706, BioGRID_ORCS_Cell_line:598, BioSample:SAMN03473269, BioSample:SAMN10987860, cancercellines:CVCL_2424, Cell_Model_Passport:SIDM01475, DepMap:ACH-001048, ECACC:07071902, EGA:EGAS00001000610, GEO:GSM886965, GEO:GSM888034, GEO:GSM1291138, GEO:GSM2474974, IARC_TP53:28258, PharmacDB:COV504_258_2019, Progenetix:CVCL_2424, Wikidata:Q54814347

ID: CVCL_2424

Record Creation Time: 20220427T215517+0000

Record Last Update: 20260829T231909+0000

Ratings and Alerts

No rating or validation information has been found for COV504.

No alerts have been found for COV504.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Liu H, et al. (2026) Ascites circRNA ASCOR Drives Platinum Resistance of High-Grade Serous Ovarian Cancer by Facilitating RPA1 Nuclear Translocation. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(23), e18922.

Yamamoto TM, et al. (2026) Chromobox 2 Inhibition: A Novel Activity of Alisertib, an Aurora A Kinase Inhibitor. *Molecular cancer therapeutics*, 25(7), 1130.

Hu Y, et al. (2025) Targeting PRDX6-dependent localization and function of GPX4 enhances ferroptosis-mediated tumor suppression. *Molecular cell*, 85(24), 4602.

Ma J, et al. (2025) Machine learning-based development of a cytotoxicity prediction model for NK cell therapy in cancers. *Cellular oncology* (Dordrecht, Netherlands), 48(6), 1837.

Persenaire C, et al. (2024) VDX-111, a novel small molecule, induces necroptosis to inhibit ovarian cancer progression. *Molecular carcinogenesis*, 63(7), 1248.

Romito O, et al. (2024) Plasma membrane SK2 channel activity regulates migration and chemosensitivity of high-grade serous ovarian cancer cells. *Molecular oncology*.

Xu Y, et al. (2023) Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma. *Cell reports*, 42(10), 113307.